Australia markets open in 8 hours 29 minutes

4D Molecular Therapeutics, Inc. (FDMT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.25-0.28 (-1.19%)
At close: 04:00PM EDT
22.77 -0.48 (-2.06%)
After hours: 07:46PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.19B
Enterprise value 915.85M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)43.90
Price/book (mrq)3.86
Enterprise value/revenue 44.19
Enterprise value/EBITDA -8.55

Trading information

Stock price history

Beta (5Y monthly) 2.86
52-week change 323.93%
S&P500 52-week change 322.36%
52-week high 336.25
52-week low 39.44
50-day moving average 328.51
200-day moving average 319.19

Share statistics

Avg vol (3-month) 31.21M
Avg vol (10-day) 3477.56k
Shares outstanding 551.16M
Implied shares outstanding 652.34M
Float 831.97M
% held by insiders 13.54%
% held by institutions 186.28%
Shares short (15 Apr 2024) 49.83M
Short ratio (15 Apr 2024) 413.13
Short % of float (15 Apr 2024) 419.93%
Short % of shares outstanding (15 Apr 2024) 419.22%
Shares short (prior month 15 Mar 2024) 48.5M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)192,905.26%

Management effectiveness

Return on assets (ttm)-23.45%
Return on equity (ttm)-37.40%

Income statement

Revenue (ttm)20.72M
Revenue per share (ttm)0.53
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -108.66M
Net income avi to common (ttm)-100.84M
Diluted EPS (ttm)-2.58
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)288.23M
Total cash per share (mrq)5.79
Total debt (mrq)14.67M
Total debt/equity (mrq)4.77%
Current ratio (mrq)15.65
Book value per share (mrq)7.15

Cash flow statement

Operating cash flow (ttm)-75.79M
Levered free cash flow (ttm)-46.48M